Logo Logo
Help
Contact
Switch language to German
The expression of Sirtuin1 and its role in ovarian cancer
The expression of Sirtuin1 and its role in ovarian cancer
SIRT1 has been a popular subject in the scientific research field since its detection in 1990. The function of this protein varies greatly depending on the tissue. Recent studies focused on SIRT1, especially in tumors. SIRT1 has been revealed to modulate cancer cell growth, metastasis, and invasion in numerous tumors. However, SIRT1 has been barely studied in gynecological tumors. The purpose of our study was to evaluate the effect of SIRT1 on ovarian cancer. First, we analyzed the relationship between the intensity of SIRT1 and RXR-alpha staining and clinical prognosis in ovarian cancer by immunohistochemistry. To further study the therapeutic effects of SIRT1 activator Resveratrol, we used MTT, M30, BrdU, and other methods to test the function of resveratrol on ovarian cancer cell lines A2780, UWB1, 289, and A2780cis, including proliferation and apoptosis. Finally, the relationship between RXR-alpha and SIRT1 proteins in ovarian cancer treated with Resveratrol was studied by western blot. Studies have shown that nuclear RXR-alpha and SIRT1-expression are significantly connected with a better outcome and overall survival rates in advanced ovarian cancer. Resveratrol had a direct effect on ovarian cancer: it suppressed the growth and proliferation of ovarian cancer cells and even increased their apoptosis. At the protein level, resveratrol (100 μM, 24h) up-regulated the expression of RXR-alpha in the anti-carboplatin cell line A2780cis and down-regulated the expression of SIRT1 in A2780. In conclusion, SIRT1 may have a suppressive role in ovarian cancer, especially in advanced ovarian cancer.
ovarian cancer, Sirt1, resveratrol, RXR
Chen, Fangfang
2022
English
Universitätsbibliothek der Ludwig-Maximilians-Universität München
Chen, Fangfang (2022): The expression of Sirtuin1 and its role in ovarian cancer. Dissertation, LMU München: Faculty of Medicine
[img]
Preview
PDF
Chen_Fangfang.pdf

2MB

Abstract

SIRT1 has been a popular subject in the scientific research field since its detection in 1990. The function of this protein varies greatly depending on the tissue. Recent studies focused on SIRT1, especially in tumors. SIRT1 has been revealed to modulate cancer cell growth, metastasis, and invasion in numerous tumors. However, SIRT1 has been barely studied in gynecological tumors. The purpose of our study was to evaluate the effect of SIRT1 on ovarian cancer. First, we analyzed the relationship between the intensity of SIRT1 and RXR-alpha staining and clinical prognosis in ovarian cancer by immunohistochemistry. To further study the therapeutic effects of SIRT1 activator Resveratrol, we used MTT, M30, BrdU, and other methods to test the function of resveratrol on ovarian cancer cell lines A2780, UWB1, 289, and A2780cis, including proliferation and apoptosis. Finally, the relationship between RXR-alpha and SIRT1 proteins in ovarian cancer treated with Resveratrol was studied by western blot. Studies have shown that nuclear RXR-alpha and SIRT1-expression are significantly connected with a better outcome and overall survival rates in advanced ovarian cancer. Resveratrol had a direct effect on ovarian cancer: it suppressed the growth and proliferation of ovarian cancer cells and even increased their apoptosis. At the protein level, resveratrol (100 μM, 24h) up-regulated the expression of RXR-alpha in the anti-carboplatin cell line A2780cis and down-regulated the expression of SIRT1 in A2780. In conclusion, SIRT1 may have a suppressive role in ovarian cancer, especially in advanced ovarian cancer.